JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

Inicio・Lista de Acciones・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Cerrado

SectorSanidad

2.18 -2.68

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.18

Máximo

2.2800000000000002

Métricas clave
By Trading Economics
Ingresos	2.6M -39M
Empleados	150
EBITDA	-1.4M -39M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+287.11% upside

Dividendos
By Dow Jones
Próximas Ganancias	12 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	212M 774M
Apertura anterior	4.86
Cierre anterior	2.18

Noticias sobre sentimiento de mercado

By Acuity

41%

59%

149 / 348 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.18 / 1.69 Soporte y Resistencia

Allogene Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

28 abr 2026, 23:33 UTC

Acciones populares

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28 abr 2026, 23:24 UTC

Ganancias

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28 abr 2026, 23:15 UTC

Noticias de Eventos Importantes

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28 abr 2026, 22:46 UTC

Ganancias

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28 abr 2026, 22:37 UTC

Ganancias

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28 abr 2026, 22:15 UTC

Ganancias

Noticias de Eventos Importantes

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28 abr 2026, 23:33 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28 abr 2026, 23:31 UTC

Ganancias

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28 abr 2026, 23:31 UTC

Ganancias

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28 abr 2026, 23:30 UTC

Ganancias

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28 abr 2026, 23:30 UTC

Ganancias

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28 abr 2026, 23:19 UTC

Charlas de Mercado

Ganancias

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28 abr 2026, 23:09 UTC

Ganancias

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28 abr 2026, 23:03 UTC

Charlas de Mercado

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28 abr 2026, 23:01 UTC

Noticias de Eventos Importantes

NIESR Sees One Rate Rise to 4% in Benign Scenario

28 abr 2026, 23:01 UTC

Noticias de Eventos Importantes

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28 abr 2026, 23:01 UTC

Noticias de Eventos Importantes

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28 abr 2026, 23:01 UTC

Noticias de Eventos Importantes

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28 abr 2026, 23:01 UTC

Noticias de Eventos Importantes

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28 abr 2026, 22:51 UTC

Ganancias

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28 abr 2026, 22:48 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

28 abr 2026, 22:48 UTC

Charlas de Mercado

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28 abr 2026, 22:40 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28 abr 2026, 22:32 UTC

Ganancias

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28 abr 2026, 22:25 UTC

Adquisiciones, fusiones, absorciones

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28 abr 2026, 22:22 UTC

Ganancias

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28 abr 2026, 22:17 UTC

Charlas de Mercado

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28 abr 2026, 22:14 UTC

Ganancias

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28 abr 2026, 22:14 UTC

Ganancias

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28 abr 2026, 22:07 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Comparación entre iguales

Cambio de precio

Allogene Therapeutics Inc previsión

Precio Objetivo

By TipRanks

287.11% repunte

Estimación a 12 Meses

Media 8.71 USD 287.11%

Máximo 14 USD

Mínimo 3.85 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Allogene Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

Comprar

Mantener

Vender

De acuerdo con 14 analistas que ofrecen calificaciones bursátiles a para Allogene Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.18 / 1.69Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentimiento

By Acuity

149 / 348 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.